FFA
ARQT icon

Farther Finance Advisors’s Arcutis Biotherapeutics ARQT Stock Holding History

Farther Finance Advisors’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.48K Sell
352
-222
-39% -$5.67K ﹤0.01% 4212
2025
Q4 		$16.7K Buy
574
+284
+98% +$7.27K ﹤0.01% 3557
2025
Q3 		$5.47K Buy
290
+217
+297% +$3.42K ﹤0.01% 3719
2025
Q2 		$1.02K Buy
73
+29
+66% +$407 ﹤0.01% 3895
2025
Q1 		$659 Hold
44
– – ﹤0.01% 3726
2024
Q4 		$613 Hold
44
– – ﹤0.01% 3401
2024
Q3 		$409 Buy
44
+14
+47% +$138 ﹤0.01% 3469
2024
Q2 		$287 Sell
30
-249
-89% -$2.25K ﹤0.01% 3410
2024
Q1 		$2.7K Buy
279
+269
+2,690% +$2.01K ﹤0.01% 2365
2023
Q4 		$32 Buy
+10
New +$27 ﹤0.01% 3424

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.69B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $8.16B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $22.9B AUM 115.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return